Hold Parameters for Midodrine
Midodrine should be held for supine systolic blood pressure ≥200 mmHg, symptomatic supine hypertension, severe bradycardia requiring intervention, urinary retention, or when the patient will be supine for extended periods (hold the dose if unable to be upright within 4 hours of administration). 1
Primary Hold Criteria
Supine Hypertension (Most Critical)
- Hold if supine systolic BP ≥180-200 mmHg - This is the most important parameter to monitor 2
- Supine hypertension occurs in approximately 10-45% of patients depending on dose (higher rates with 20 mg doses) 3, 1
- The FDA label explicitly states midodrine should be stopped if supine blood pressure increases excessively 1
- Long-term use associated with supine systolic hypertension in <10% of patients, warranting cessation 2
Timing-Related Holds
- Do not administer after evening meal or within 4 hours of bedtime to reduce supine hypertension risk during sleep 1
- Hold if patient cannot remain upright - Midodrine should only be given when patient needs to be upright pursuing activities of daily living 1
- Doses should be given during daytime hours with suggested intervals of approximately 4 hours (can be 3 hours if needed) 1
Bradycardia
- Monitor for and hold if significant bradycardia develops - Midodrine causes reflex parasympathetic stimulation 2
- In one case series, transient bradycardia required discontinuation in one patient 4
- Use extreme caution with other negative chronotropic agents (beta-blockers, digoxin, non-dihydropyridine calcium channel blockers) 2
Urinary Retention
- Hold if urinary retention develops - This is a known adverse effect 3, 5
- Midodrine can antagonize alpha-adrenergic blockers (terazosin, prazosin, doxazosin) and worsen urinary retention 2
Clinical Context Considerations
Heart Failure Patients
- Use with extreme caution in CHF patients - Midodrine may be poorly tolerated due to increased afterload 2, 6, 2
- Recent evidence suggests potential increased mortality risk in HFrEF patients, though data are conflicting 7, 8
- Consider holding if signs of decompensation develop
Drug Interactions Requiring Hold
- Avoid concomitant use with other alpha-adrenergic agonists (ephedrine, pseudoephedrine, phenylpropanolamine) as this aggravates supine hypertension 2
Renal Dysfunction
- In patients with abnormal renal function, consider holding if creatinine clearance deteriorates significantly, as desglymidodrine (active metabolite) is renally cleared 1
- Midodrine is removed by hemodialysis 1
Monitoring Parameters to Guide Holding
Check these before each dose:
- Supine blood pressure (most critical)
- Standing blood pressure 1 hour post-dose
- Heart rate for bradycardia
- Urinary symptoms
The medication should be discontinued entirely if:
- Patient does not achieve symptomatic improvement during initial treatment 1
- Supine hypertension persists despite dose adjustment
- Severe adverse effects develop (ischemia, persistent bradycardia, urinary retention)
Common Pitfalls
- Giving doses too late in the day - The last dose must be at least 4 hours before bedtime 1
- Not checking supine BP - This is the most dangerous adverse effect and requires routine monitoring 3, 1
- Continuing therapy without symptomatic benefit - FDA guidance is clear that midodrine should only be continued if patients show improvement 1
- Ignoring the 4-hour upright requirement - Patients must be able to remain upright after dosing 1